A radiomics-based decision support tool improves lung cancer diagnosis in combination with the Herder score in large lung nodules
Benjamin Hunter(Royal Marsden NHS Foundation Trust), Richard W. Lee(Royal Marsden NHS Foundation Trust), Nishanthi Senthivel(Royal Marsden NHS Foundation Trust), Bhavin Rawal(Harefield Hospital), Stan B. Kaye(Institute of Cancer Research), Neal Navani(University College London Hospitals NHS Foundation Trust), Daniel Tong(Royal Marsden NHS Foundation Trust), Matthew Blackledge(Institute of Cancer Research), Prashanthi Ratnakumar(Charing Cross Hospital), Mitchell Chen(Imperial College London), Anand Devaraj(Royal Brompton & Harefield NHS Foundation Trust), Simon Doran(Institute of Cancer Research), Laura Boddy(Royal Marsden NHS Foundation Trust), Catey Bunce(Moorfields Eye Hospital NHS Foundation Trust), S. Gareeboo(Queen Elizabeth Hospital), Arjun Nair(University College London Hospitals NHS Foundation Trust), Samuel V. Kemp(Nottingham University Hospitals NHS Trust), Kristofer Linton‐Reid(Imperial College London), Eric O. Aboagye(Hammersmith Hospital), Sejal Jain(Royal Marsden NHS Foundation Trust), Andrew Logan(Imperial College London), Susannah Bloch(Charing Cross Hospital), Amyn Bhamani(Living Streets)
Cited by 46
Related Papers
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
|The Lancet Respiratory Medicine|2020|558
Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.
|Journal of Clinical Oncology|1997|334